Millennium Management LLC Sells 1,655,703 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Millennium Management LLC cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 45.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,000,903 shares of the company’s stock after selling 1,655,703 shares during the quarter. Millennium Management LLC owned approximately 0.06% of Takeda Pharmaceutical worth $26,492,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Blair William & Co. IL raised its holdings in shares of Takeda Pharmaceutical by 8.1% in the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company’s stock valued at $162,000 after buying an additional 913 shares during the last quarter. Sage Rhino Capital LLC raised its holdings in shares of Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company’s stock valued at $157,000 after buying an additional 1,538 shares during the last quarter. Aaron Wealth Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 7.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock valued at $331,000 after buying an additional 1,670 shares during the last quarter. OLD Mission Capital LLC raised its holdings in shares of Takeda Pharmaceutical by 13.7% in the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company’s stock valued at $185,000 after buying an additional 1,687 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company’s stock valued at $69,000 after buying an additional 1,770 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $14.24 on Tuesday. The stock has a 50-day simple moving average of $14.75 and a 200 day simple moving average of $14.00. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.43. The stock has a market capitalization of $45.31 billion, a price-to-earnings ratio of 35.60, a P/E/G ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.08). The firm had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.